HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Stang, P. Articles by Keating, E. T. Search for Related Content PubMed PubMed Citation Articles by Stang, P. Articles by Keating, E. T.

The Prevalence of COPD^*

Using Smoking Rates to Estimate Disease Frequency in the General Population

^* From Galt Associates (Dr. Stang), Sterling, VA; SmithKline Beecham Pharmaceuticals (Drs. Lydick and Silberman and Ms. Keating), Collegeville, PA; and Pharmametrics GmbH (Dr. Kempel), Freiburg, Germany.

Correspondence to: Paul Stang, PhD, 1744 Dekalb Pike, Suite 175, Blue Bell, PA 19422; e-mail: pstang{at}galt-assoc.com

Study objectives: To develop and validate a model based on smoking rates that will provide reliable estimates of the true prevalence of COPD that include both clinically detected and undetected patients.

Design: Model based on literature review. Age- and gender-specific rates of lung impairment by smoking status were applied to US smoking data. Resultant estimates were compared to the actual prevalence of obstructive airway disease as estimated by US national surveys. The model then was applied to estimate the prevalence of COPD in several European countries, where national data on undiagnosed lung disease do not exist.

Setting: The model was adapted from both a literature review and health-care data, and the analysis was applied to the United States and Europe.

Results: Using smoking rates, we estimate from our model that 15.3 million people who are > 40 years of age in the United States have COPD. The prevalence estimate, based on spirometric definitions for COPD in the same age group using the Third National Health and Nutrition Examination Survey (NHANES III), is 17.1 million people. NHANES III and other US national health-care surveys further suggest that only between 2.4 and 7 million people actually have COPD diagnosed; thus, the proportion of COPD that is currently being diagnosed in the United States is between 14% and 46% of all cases. Using smoking rates and our model, which was developed and validated for the United States, we calculated the prevalence of COPD for Germany (2.7 million people), the United Kingdom (3.0 million people), Spain (1.5 million people), Italy (2.6 million people), and France (2.6 million people) in those people > 45 years of age.

Conclusions: Smoking rates appear to provide a useful method of estimating current COPD prevalence in those countries where more objective data are unavailable. These results are important because recognition of the true burden of disease and corresponding efforts to increase early identification of COPD can help to reduce the morbidity and mortality associated with COPD in populations at risk.

Key Words: COPD • prevalence • smoking

This article has been cited by other articles:

				D. Price and M. Duerden Chronic obstructive pulmonary disease BMJ, May 15, 2003; 326(7398): 1046 - 1047. [Full Text] [PDF]

				R. J. Halbert, S. Isonaka, D. George, and A. Iqbal Interpreting COPD Prevalence Estimates: What Is the True Burden of Disease? Chest, May 1, 2003; 123(5): 1684 - 1692. [Abstract] [Full Text] [PDF]

				B. Lundback, A. Gulsvik, M. Albers, P. Bakke, E. Ronmark, G. van den Boom, J. Brogger, L-G. Larsson, I. Welle, C. van Weel, et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly Eur. Respir. J., May 1, 2003; 21(40_suppl): 3S - 9s. [Abstract] [Full Text] [PDF]

				T. L. Croxton, G. G. Weinmann, R. M. Senior, R. A. Wise, J. D. Crapo, and A. S. Buist Clinical Research in Chronic Obstructive Pulmonary Disease: Needs and Opportunities Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1142 - 1149. [Abstract] [Full Text] [PDF]

				M. Miravitlles, C. Murio, T. Guerrero, and R. Gisbert Costs of Chronic Bronchitis and COPD: A 1-Year Follow-up Study Chest, March 1, 2003; 123(3): 784 - 791. [Abstract] [Full Text] [PDF]

				R. G. Barr, J. Herbstman, F. E. Speizer, and C. A. Camargo Jr. Validation of Self-reported Chronic Obstructive Pulmonary Disease in a Cohort Study of Nurses Am. J. Epidemiol., May 15, 2002; 155(10): 965 - 971. [Abstract] [Full Text] [PDF]

				T. L. CROXTON, G. G. WEINMANN, R. M. SENIOR, and J. R. HOIDAL Future Research Directions in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 838 - 844. [Full Text] [PDF]